Design Therapeutics Analyst Ratings
Design Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 79.36% | RBC Capital | $7 → $4 | Maintains | Sector Perform |
| 08/15/2023 | 169.05% | Wedbush | → $6 | Downgrades | Outperform → Neutral |
| 08/15/2023 | 169.05% | SVB Leerink | → $6 | Downgrades | Outperform → Market Perform |
| 08/15/2023 | 213.89% | RBC Capital | $23 → $7 | Downgrades | Outperform → Sector Perform |
| 05/10/2023 | 931.34% | RBC Capital | $24 → $23 | Maintains | Outperform |
| 05/10/2023 | 751.98% | Wedbush | $20 → $19 | Maintains | Outperform |
| 05/04/2023 | — | Goldman Sachs | Upgrades | Sell → Neutral | |
| 03/15/2023 | 976.18% | RBC Capital | → $24 | Reiterates | → Outperform |
| 12/09/2022 | 886.5% | SVB Leerink | $30 → $22 | Maintains | Outperform |
| 12/08/2022 | 976.18% | RBC Capital | $29 → $24 | Maintains | Outperform |
| 08/09/2022 | 1065.87% | Wedbush | $21 → $26 | Maintains | Outperform |
| 06/10/2022 | 841.66% | Wedbush | → $21 | Initiates Coverage On | → Outperform |
| 05/24/2022 | 169.05% | Goldman Sachs | $8 → $6 | Maintains | Sell |
| 05/10/2022 | 1245.23% | SVB Leerink | $36 → $30 | Maintains | Outperform |
| 05/02/2022 | 1245.23% | RBC Capital | → $30 | Initiates Coverage On | → Outperform |
| 01/19/2022 | 348.41% | Goldman Sachs | → $10 | Initiates Coverage On | → Sell |
| 04/20/2021 | 1514.28% | SVB Leerink | → $36 | Initiates Coverage On | → Outperform |
| 04/20/2021 | 1155.55% | Goldman Sachs | → $28 | Initiates Coverage On | → Neutral |
| 04/20/2021 | 1783.32% | Piper Sandler | → $42 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/14/2023 | 79.36% | 加拿大皇家银行资本 | 7 美元 → 4 美元 | 维护 | 行业表现 |
| 08/15/2023 | 169.05% | Wedbush | → 6 美元 | 降级 | 跑赢大盘 → 中性 |
| 08/15/2023 | 169.05% | SVB Leerink | → 6 美元 | 降级 | 跑赢大盘 → 市场表现 |
| 08/15/2023 | 213.89% | 加拿大皇家银行资本 | 23 美元 → 7 美元 | 降级 | 跑赢大盘 → 行业表现 |
| 05/10/2023 | 931.34% | 加拿大皇家银行资本 | 24 美元 → 23 美元 | 维护 | 跑赢大盘 |
| 05/10/2023 | 751.98% | Wedbush | 20 美元 → 19 美元 | 维护 | 跑赢大盘 |
| 05/04/2023 | — | 高盛 | 升级 | 卖出 → 中立 | |
| 03/15/2023 | 976.18% | 加拿大皇家银行资本 | → 24 美元 | 重申 | → 跑赢大盘 |
| 2022 年 9 月 12 日 | 886.5% | SVB Leerink | 30 美元 → 22 美元 | 维护 | 跑赢大盘 |
| 2022 年 8 月 12 日 | 976.18% | 加拿大皇家银行资本 | 29 美元 → 24 美元 | 维护 | 跑赢大盘 |
| 08/09/2022 | 1065.87% | Wedbush | 21 美元 → 26 美元 | 维护 | 跑赢大盘 |
| 06/10/2022 | 841.66% | Wedbush | → 21 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2022 年 5 月 24 日 | 169.05% | 高盛 | 8 美元 → 6 美元 | 维护 | 卖出 |
| 05/10/2022 | 1245.23% | SVB Leerink | 36 美元 → 30 美元 | 维护 | 跑赢大盘 |
| 05/02/2022 | 1245.23% | 加拿大皇家银行资本 | → 30 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2022 年 1 月 19 日 | 348.41% | 高盛 | → 10 美元 | 启动覆盖范围开启 | → 卖出 |
| 04/20/2021 | 1514.28% | SVB Leerink | → 36 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 04/20/2021 | 1155.55% | 高盛 | → 28 美元 | 启动覆盖范围开启 | → 中立 |
| 04/20/2021 | 1783.32% | 派珀·桑德勒 | → 42 美元 | 启动覆盖范围开启 | → 超重 |
What is the target price for Design Therapeutics (DSGN)?
Design Therapeutics（DSGN）的目标价格是多少？
The latest price target for Design Therapeutics (NASDAQ: DSGN) was reported by RBC Capital on November 14, 2023. The analyst firm set a price target for $4.00 expecting DSGN to rise to within 12 months (a possible 79.36% upside). 10 analyst firms have reported ratings in the last year.
加拿大皇家银行资本于2023年11月14日公布了Design Therapeutics（纳斯达克股票代码：DSGN）的最新目标股价。该分析公司将目标股价定为4.00美元，预计DSGN将在12个月内升至12个月内（可能上涨79.36％）。去年有10家分析公司公布了评级。
What is the most recent analyst rating for Design Therapeutics (DSGN)?
分析师对Design Therapeutics（DSGN）的最新评级是多少？
The latest analyst rating for Design Therapeutics (NASDAQ: DSGN) was provided by RBC Capital, and Design Therapeutics maintained their sector perform rating.
加拿大皇家银行资本对Design Therapeutics（纳斯达克股票代码：DSGN）的最新分析师评级由加拿大皇家银行资本提供，Design Therapeutics维持其行业表现评级。
When is the next analyst rating going to be posted or updated for Design Therapeutics (DSGN)?
Design Therapeutics（DSGN）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Design Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Design Therapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Design Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Design Therapeutics的最新评级是在2023年11月14日发布的，因此您应该预计下一个评级将在2024年11月14日左右公布。
Is the Analyst Rating Design Therapeutics (DSGN) correct?
分析师评级 Design Therapeutics (DSGN) 是否正确？
While ratings are subjective and will change, the latest Design Therapeutics (DSGN) rating was a maintained with a price target of $7.00 to $4.00. The current price Design Therapeutics (DSGN) is trading at is $2.23, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Design Therapeutics（DSGN）评级保持不变，目标股价为7.00美元至4.00美元。Design Therapeutics（DSGN）目前的交易价格为2.23美元，超出了分析师的预期区间。